BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vakil N, Megraud F. Eradication Therapy for Helicobacter pylori. Gastroenterology 2007;133:985-1001. [DOI: 10.1053/j.gastro.2007.07.008] [Cited by in Crossref: 154] [Cited by in F6Publishing: 151] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Huang Y, Zhan X. Sequential Therapy is Superior to Triple Therapy for Helicobacter pylori Infection in Children: A Meta-Analysis. Indian J Pediatr 2016;83:307-15. [DOI: 10.1007/s12098-015-1878-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
2 Caro SD, Fini L, Daoud Y, Grizzi F, Gasbarrini A, Lorenzo AD, Renzo LD, McCartney S, Bloom S. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol 2012; 18(40): 5669-5678 [PMID: 23155306 DOI: 10.3748/wjg.v18.i40.5669] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
3 Wee EW. Evidence-based approach to dyspepsia: from Helicobacter pylori to functional disease. Postgrad Med 2013;125:169-80. [PMID: 23933904 DOI: 10.3810/pgm.2013.07.2688] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Gatta L, Scarpignato C, Fiorini G, Belsey J, Saracino IM, Ricci C, Vaira D. Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Aliment Pharmacol Ther 2018;47:1261-9. [DOI: 10.1111/apt.14597] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
5 Miendje Deyi VY, Bontems P, Vanderpas J, De Koster E, Ntounda R, Van den Borre C, Cadranel S, Burette A. Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium. J Clin Microbiol. 2011;49:2200-2209. [PMID: 21450969 DOI: 10.1128/jcm.02642-10] [Cited by in Crossref: 54] [Cited by in F6Publishing: 18] [Article Influence: 4.9] [Reference Citation Analysis]
6 Calhan T, Kahraman R, Sahin A, Senates E, Doganay HL, Kanat E, Ozdil K, Sokmen HM. Efficacy of two levofloxacin-containing second-line therapies for Helicobacter pylori: a pilot study. Helicobacter. 2013;18:378-383. [PMID: 23601026 DOI: 10.1111/hel.12056] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
7 Binh TT, Shiota S, Suzuki R, Matsuda M, Trang TT, Kwon DH, Iwatani S, Yamaoka Y. Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. J Antimicrob Chemother. 2014;69:1796-1803. [PMID: 24648504 DOI: 10.1093/jac/dku050] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
8 Liou JM, Chen PY, Kuo YT, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Toward population specific and personalized treatment of Helicobacter pylori infection. J Biomed Sci 2018;25:70. [PMID: 30285834 DOI: 10.1186/s12929-018-0471-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
9 Sezikli M, Çetinkaya ZA, Güzelbulut F, Çimen B, Özcan Ö, Özkara S, Yeşil A, Gümrükçü G, İpçioğlu OM, Sezikli H, Övünç AOK. Effects of Alpha Tocopherol and Ascorbic Acid on Helicobacter pylori Colonization and the Severity of Gastric Inflammation: Effects of antioxidants on Helicobacter pylori gastritis. Helicobacter 2012;17:127-32. [DOI: 10.1111/j.1523-5378.2011.00925.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
10 Felga GEG, Silva FM, Barbuti RC, Navarro-Rodriguez T, Zaterka S, Eisig JN. Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. World J Gastroenterol 2008; 14(40): 6224-6227 [PMID: 18985815 DOI: 10.3748/wjg.14.6224] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
11 Alazmi WM, Buhaimed W, Al-mekhaizeem K, Siddique I. Efficacy of Standard Triple Therapy in the Treatment of Helicobacter pylori Infection: Experience from Kuwait. Dig Dis Sci 2010;55:3120-3. [DOI: 10.1007/s10620-010-1139-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Blaser MJ. Helicobacter pylori and Other Gastric Helicobacter Species. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 2803-13. [DOI: 10.1016/b978-0-443-06839-3.00217-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Auesomwang C, Maneerattanaporn M, Chey WD, Kiratisin P, Leelakusolwong S, Tanwandee T. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication. J Gastroenterol Hepatol. 2018;33:1822-1828. [PMID: 29804294 DOI: 10.1111/jgh.14292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
14 Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol. 2009;104:3069-79; quiz 1080. [PMID: 19844205 DOI: 10.1038/ajg.2009.555] [Cited by in Crossref: 188] [Cited by in F6Publishing: 199] [Article Influence: 14.5] [Reference Citation Analysis]
15 Hagymási K, Tulassay Z. The new aspects of the eradication of Helicobacter pylori and the importance of bacterial resistance. Orvosi Hetilap 2008;149:2029-35. [DOI: 10.1556/oh.2008.28460] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
16 Busse M, Trinh I, Junk PC, Ferrero RL, Andrews PC. Synthesis and characterisation of bismuth(III) aminoarenesulfonate complexes and their powerful bactericidal activity against Helicobacter pylori. Chemistry 2013;19:5264-75. [PMID: 23536213 DOI: 10.1002/chem.201204220] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
17 Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol. 2010;8:36-41.e1. [PMID: 19804842 DOI: 10.1016/j.cgh.2009.09.030] [Cited by in Crossref: 162] [Cited by in F6Publishing: 168] [Article Influence: 12.5] [Reference Citation Analysis]
18 Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther. 2016;23:e880-e893. [PMID: 25569598 DOI: 10.1097/mjt.0000000000000191] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 4.4] [Reference Citation Analysis]
19 Andrews PC, Ferrero RL, Junk PC, Peiris RM. A sweeter way to combat Helicobacter pylori? Bismuth(III) complexes and oxido-clusters derived from non-nutritive sweeteners and their activity against H. pylori. Journal of Organometallic Chemistry 2013;724:88-94. [DOI: 10.1016/j.jorganchem.2012.10.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Sainsus N, Cattori V, Lepadatu C, Hofmann-Lehmann R. Liquid culture medium for the rapid cultivation of Helicobacter pylori from biopsy specimens. Eur J Clin Microbiol Infect Dis 2008;27:1209-17. [PMID: 18604574 DOI: 10.1007/s10096-008-0567-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
21 Cover TL, Blaser MJ. Helicobacter pylori and Other Gastric Helicobacter Species. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2015. pp. 2494-2502.e4. [DOI: 10.1016/b978-1-4557-4801-3.00219-8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Binh TT, Suzuki R, Shiota S, Kwon DH, Yamaoka Y. Complete Genome Sequences of Helicobacter pylori Clarithromycin-Resistant Strains. Genome Announc 2013;1:e00912-13. [PMID: 24233587 DOI: 10.1128/genomeA.00912-13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Bai P, Zhou LY, Xiao XM, Luo Y, Ding Y. Susceptibility of Helicobacter pylori to antibiotics in Chinese patients. J Dig Dis. 2015;16:464-470. [PMID: 26147515 DOI: 10.1111/1751-2980.12271] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
24 Nkuize M, Vanderpas J, Buset M, Delforge M, Cadière GB, De Wit S. Failure to eradicate Helicobacter pylori infection is more frequent among HIV-positive patients. HIV Med 2021;22:547-56. [PMID: 33765332 DOI: 10.1111/hiv.13083] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Lee H, Hong SN, Min BH, Lee JH, Rhee PL, Lee YC, Kim JJ. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea. Dig Liver Dis. 2015;47:114-118. [PMID: 25467826 DOI: 10.1016/j.dld.2014.10.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
26 Huang CC, Tsai KW, Tsai TJ, Hsu PI. Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy. Biomark Res 2017;5:23. [PMID: 28702193 DOI: 10.1186/s40364-017-0103-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
27 Chung WC, Jung SH, Oh JH, Kim TH, Cheung DY, Kim BW, Kim SS, Kim JI, Sin EY. Dual-priming oligonucleotide-based multiplex PCR using tissue samples in rapid urease test in the detection of Helicobacter pylori infection. World J Gastroenterol 2014; 20(21): 6547-6553 [PMID: 24914376 DOI: 10.3748/wjg.v20.i21.6547] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
28 Li H, Yang T, Tang H, Tang X, Shen Y, Benghezal M, Tay A, Marshall B. Helicobacter pylori infection is an infectious disease and the empiric therapy paradigm should be changed. Precision Clinical Medicine 2019;2:77-80. [DOI: 10.1093/pcmedi/pbz009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
29 Yang JC, Lee PI, Hsueh PR. In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007. Eur J Clin Microbiol Infect Dis. 2010;29:1369-1375. [PMID: 20658256 DOI: 10.1007/s10096-010-1009-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
30 Peek RM Jr. New Biology to New Treatment of Helicobacter pylori-Induced Gastric Cancer. Dig Dis 2016;34:510-6. [PMID: 27332886 DOI: 10.1159/000445231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
31 Kim JS, Kim BW, Ham JH, Park HW, Kim YK, Lee MY, Ji JS, Lee BI, Choi H. Sequential Therapy for Helicobacter pylori Infection in Korea: Systematic Review and Meta-Analysis. Gut Liver 2013;7:546-51. [PMID: 24073312 DOI: 10.5009/gnl.2013.7.5.546] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
32 Mégraud F. Helicobacter pylori : caractères bactériologiques, méthodes diagnostiques et sensibilité aux antibiotiques. La Presse Médicale 2008;37:507-12. [DOI: 10.1016/j.lpm.2007.07.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, Guo F, Ji Z, Mao J, Tang W, Shi Z, Shao W, Zhu X, Zhang X, Tong Y, Tu H, Jiang M, Wang Z, Jin F, Yang N. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter. 2013;18:274-279. [PMID: 23418857 DOI: 10.1111/hel.12046] [Cited by in Crossref: 96] [Cited by in F6Publishing: 97] [Article Influence: 10.7] [Reference Citation Analysis]
34 Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, Wang HM, Tsai TJ, Wu DC, Chen CL, Tsai KW; Taiwan Acid-related Disease (TARD) Study Group. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. Helicobacter 2018;23:e12498. [PMID: 29897654 DOI: 10.1111/hel.12498] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
35 McMahon BJ, Bruce MG, Koch A, Goodman KJ, Tsukanov V, Mulvad G, Borresen ML, Sacco F, Barrett D, Westby S, Parkinson AJ. The diagnosis and treatment of Helicobacter pylori infection in Arctic regions with a high prevalence of infection: Expert Commentary. Epidemiol Infect 2016;144:225-33. [PMID: 26094936 DOI: 10.1017/S0950268815001181] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 4.1] [Reference Citation Analysis]
36 Park H, Kim CO, Kim M, Lim Y, Lee WY, Yoon S, Park MS. Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects. Transl Clin Pharmacol 2020;28:136-46. [PMID: 33062627 DOI: 10.12793/tcp.2020.28.e16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Del Giudice G, Malfertheiner P, Rappuoli R. Development of vaccines against Helicobacter pylori. Expert Rev Vaccines. 2009;8:1037-1049. [PMID: 19627186 DOI: 10.1586/erv.09.62] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
38 Kim JH. Recent Update on Third-line Helicobacter pylori Eradication. Korean J Helicobacter Up Gastrointest Res 2015;15:89. [DOI: 10.7704/kjhugr.2015.15.2.89] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
39 Mannion A, Dzink-Fox J, Shen Z, Piazuelo MB, Wilson KT, Correa P, Peek RM Jr, Camargo MC, Fox JG. Helicobacter pylori Antimicrobial Resistance and Gene Variants in High- and Low-Gastric-Cancer-Risk Populations. J Clin Microbiol 2021;59:e03203-20. [PMID: 33692136 DOI: 10.1128/JCM.03203-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 González-Huezo MS, Rojas-Sánchez A, Rosales-Solís AA, Miranda-Cordero RM, Hinojosa-Ruiz A, Mejía-García E, Cruz-González EG. [Helicobacter pylori eradication frequency with the conventional triple therapy in adult patients at the Centro Médico Issemym]. Rev Gastroenterol Mex. 2012;77:114-118. [PMID: 22921101 DOI: 10.1016/j.rgmx.2012.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
41 Abadi AT, Taghvaei T, Mobarez AM, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J Microbiol 2011;49:987-93. [PMID: 22203563 DOI: 10.1007/s12275-011-1170-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
42 Schmitt BH, Regner M, Mangold KA, Thomson RB, Kaul KL. PCR detection of clarithromycin-susceptible and -resistant Helicobacter pylori from formalin-fixed, paraffin-embedded gastric biopsies. Mod Pathol. 2013;26:1222-1227. [PMID: 23579617 DOI: 10.1038/modpathol.2013.48] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
43 Gatta L, Di Mario F, Vaira D, Franzé A, Rugge M, Pilotto A, Lucarini P, Lera M, Fiorini G, Castelli V, Kajo E, Scarpignato C. Helicobacter pylori eradication: are we really all equal? A controlled study in native and immigrant population. Intern Emerg Med 2011;6:35-9. [DOI: 10.1007/s11739-010-0443-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
44 Manfredi M, Bizzarri B, Sacchero RI, Maccari S, Calabrese L, Fabbian F, De'Angelis GL. Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy. Helicobacter. 2012;17:254-263. [PMID: 22759324 DOI: 10.1111/j.1523-5378.2012.00944.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
45 Saracino IM, Fiorini G, Zullo A, Pavoni M, Saccomanno L, Vaira D. Trends in Primary Antibiotic Resistance in H. pylori Strains Isolated in Italy between 2009 and 2019. Antibiotics (Basel) 2020;9:E26. [PMID: 31941121 DOI: 10.3390/antibiotics9010026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
46 Khien VV, Thang DM, Hai TM, Duat NQ, Khanh PH, Ha DT, Binh TT, Dung HDQ, Trang TTH, Yamaoka Y. Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam. Gut Liver 2019;13:483-97. [PMID: 31009957 DOI: 10.5009/gnl18137] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
47 Lahbabi M, Loukili B, Berreho A, Tachfouti N, Elyousfi M, Mellouki I, Aqodad N, Elabkari M, Elrhazi K, Nejjari C, Benajah D, Ibrahimi A. Éradication d’H. pylori dans les ulcères bulbaires: quelle trithérapie de première intention? Résultats d’une étude prospective randomisée comparant le métronidazole à la clarithromycine. J Afr Hepato Gastroenterol 2012;6:18-23. [DOI: 10.1007/s12157-011-0338-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
48 Kutluk G, Tutar E, Bayrak A, Volkan B, Akyon Y, Celikel C, Ertem D. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains? Eur J Gastroenterol Hepatol. 2014;26:1202-1208. [PMID: 25171023 DOI: 10.1097/meg.0000000000000190] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
49 Lien HM, Wu HY, Hung CL, Chen CJ, Wu CL, Chen KW, Huang CL, Chang SJ, Chen CC, Lin HJ, Lai CH. Antibacterial activity of ovatodiolide isolated from Anisomeles indica against Helicobacter pylori. Sci Rep 2019;9:4205. [PMID: 30862888 DOI: 10.1038/s41598-019-40735-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
50 Fakheri H, Taghvaei T, Hosseini V, Bari Z. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial. Helicobacter. 2012;17:43-48. [PMID: 22221615 DOI: 10.1111/j.1523-5378.2011.00896.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
51 Vale FF, Vítor JM. Transmission pathway of Helicobacter pylori: does food play a role in rural and urban areas? Int J Food Microbiol. 2010;138:1-12. [PMID: 20122750 DOI: 10.1016/j.ijfoodmicro.2010.01.016] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 6.0] [Reference Citation Analysis]
52 Lee SK, Lee SW, Park JY, Kwon BS, Kim SY, Hyun JJ, Kim JH, Jung SW, Koo JS, Yim HJ. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy. Helicobacter. 2011;16:410-414. [PMID: 21923688 DOI: 10.1111/j.1523-5378.2011.00870.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
53 Raval J, Patel J, Patel M. Formulation and in vitro characterization of spray dried microspheres of amoxicillin. Acta Pharmaceutica 2010;60. [DOI: 10.2478/v10007-010-0034-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
54 Federico A, Gravina AG, Miranda A, Loguercio C, Romano M. Eradication of Helicobacter pylori infection: Which regimen first? World J Gastroenterol 2014; 20(3): 665-672 [PMID: 24574740 DOI: 10.3748/wjg.v20.i3.665] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
55 Liou J, Chen P, Luo J, Lee J, Chen C, Fang Y, Yang T, Chang C, Bair M, Chen M, Hsu Y, Hsu W, Chang C, Lin J, Shun C, El-omar EM, Wu M, Liou J, Lee Y, Lin J, Wu C, Wu J, Chen C, Lin C, Fang Y, Bair M, Luo J, Wu M, Cheng T, Tseng P, Chiu H, Chang C, Yu C, Chiu M, Chen Y, Hu W, Chou C, Tai C, Lee C, Wang W, Chang W. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection. Gastroenterology 2018;155:1109-19. [DOI: 10.1053/j.gastro.2018.06.047] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
56 Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, Antonelli G, Cavallo R, Borghi C, Vaira D. Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection. European Journal of Internal Medicine 2020;81:50-3. [DOI: 10.1016/j.ejim.2020.06.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
57 Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:109-118. [PMID: 19298338 DOI: 10.1111/j.1523-5378.2009.00671] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
58 Huang J, Zhou L, Geng L, Yang M, Xu XW, Ding ZL, Mao M, Wang ZL, Li ZL, Li DY, Gong ST. Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. Aliment Pharmacol Ther. 2013;38:1230-1235. [PMID: 24117692 DOI: 10.1111/apt.12516] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
59 Liou JM, Chen CC, Lee YC, Chang CY, Wu JY, Bair MJ, Lin JT, Chen MJ, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2016;43:470-481. [PMID: 26669729 DOI: 10.1111/apt.13495] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
60 Alkim H, Iscan M, Oz F. Effectiveness of ranitidine bismuth citrate and proton pump inhibitor based triple therapies of Helicobacter pylori in Turkey. Libyan J Med. 2011;6. [PMID: 21912572 DOI: 10.3402/ljm.v6i0.8412] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
61 Sethi V, Vitiello GA, Saxena D, Miller G, Dudeja V. The Role of the Microbiome in Immunologic Development and its Implication For Pancreatic Cancer Immunotherapy. Gastroenterology 2019;156:2097-2115.e2. [DOI: 10.1053/j.gastro.2018.12.045] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
62 Urgesi R, Pelecca G, Cianci R, Masini A, Zampaletta C, Riccioni ME, Faggiani R. Helicobacter pylori infection: is sequential therapy superior to standard triple therapy? A single-centre Italian study in treatment-naive and non-treatment-naive patients. Can J Gastroenterol 2011;25:315-8. [PMID: 21766091 DOI: 10.1155/2011/967671] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
63 Chen H, Dang Y, Zhou X, Liu B, Liu S, Zhang G. Tailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication: A Meta-Analysis. Medicine (Baltimore). 2016;95:e2750. [PMID: 26886617 DOI: 10.1097/md.0000000000002750] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
64 Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:109-118. [PMID: 19298338 DOI: 10.1111/j.1523-5378.2009.00671x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Gehlot V, Mahant S, Mukhopadhyay AK, Das K, Alam J, Ghosh P, Das R. Low prevalence of clarithromycin-resistant Helicobacter pylori isolates with A2143G point mutation in the 23S rRNA gene in North India. J Glob Antimicrob Resist. 2016;6:39-43. [PMID: 27530837 DOI: 10.1016/j.jgar.2016.02.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
66 Song M, Ang TL. Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol 2014; 20(6): 1517-1528 [PMID: 24587627 DOI: 10.3748/wjg.v20.i6.1517] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
67 Sirimontaporn N, Thong-Ngam D, Tumwasorn S, Mahachai V. Ten-day sequential therapy of Helicobacter pylori infection in Thailand. Am J Gastroenterol. 2010;105:1071-1075. [PMID: 20010919 DOI: 10.1038/ajg.2009.708] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
68 Almeida N, Donato MM, Romãozinho JM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Fernandes A, Calhau C, Sofia C. Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country? BMC Gastroenterol 2015;15:23. [PMID: 25886722 DOI: 10.1186/s12876-015-0245-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
69 Gatta L, Di Mario F, Vaira D, Rugge M, Franzè A, Plebani M, Cavestro GM, Lucarini P, Lera M, Scarpignato C. Quantification of serum levels of pepsinogens and gastrin to assess eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2011;9:440-2. [PMID: 21172454 DOI: 10.1016/j.cgh.2010.12.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
70 Hsu P, Pan C, Kao JY, Tsay F, Peng N, Kao S, Chen Y, Tsai T, Wu D, Tsai K. Short‐term and long‐term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota. Journal of Gastroenterology and Hepatology 2019;34:1968-76. [DOI: 10.1111/jgh.14736] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
71 Zhou JJ, Shi X, Zheng SP, Tang D, Cai T, Yao Y, Wang F. Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: A large-scale prospective, single-center clinical trial in China. Helicobacter 2020;25:e12755. [PMID: 32914914 DOI: 10.1111/hel.12755] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008;5:321-331. [PMID: 18446147 DOI: 10.1038/ncpgasthep1138] [Cited by in Crossref: 212] [Cited by in F6Publishing: 226] [Article Influence: 15.1] [Reference Citation Analysis]
73 Song H, Lv X, Yang J, Liu W, Yang H, Xi T, Xing Y. A novel chimeric flagellum fused with the multi-epitope vaccine CTB-UE prevents Helicobacter pylori-induced gastric cancer in a BALB/c mouse model. Appl Microbiol Biotechnol 2015;99:9495-502. [DOI: 10.1007/s00253-015-6705-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
74 Tai WC, Lee CH, Chiou SS, Kuo CM, Kuo CH, Liang CM, Lu LS, Chiu CH, Wu KL, Chiu YC. The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication. PLoS One. 2014;9:e105822. [PMID: 25141137 DOI: 10.1371/journal.pone.0105822] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
75 Huang HT, Wang HM, Yang SC, Tai WC, Liang CM, Wu KL, Lee CH, Chuah SK. Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication. Infect Drug Resist 2018;11:2073-80. [PMID: 30464550 DOI: 10.2147/IDR.S185511] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
76 Wassenaar TM, Silley P. Antimicrobial resistance in zoonotic bacteria: lessons learned from host-specific pathogens. Anim Health Res Rev 2008;9:177-86. [DOI: 10.1017/s1466252308001539] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
77 Peura DA, Crowe SE. Helicobacter pylori. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Elsevier; 2010. pp. 833-843.e4. [DOI: 10.1016/b978-1-4160-6189-2.00050-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
78 Shahid SK. Novel anti-Helicobacter pylori therapies. Pharm Pat Anal 2014;3:411-27. [PMID: 25291314 DOI: 10.4155/ppa.14.27] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
79 Jones JE, Causey CP, Lovelace L, Knuckley B, Flick H, Lebioda L, Thompson PR. Characterization and inactivation of an agmatine deiminase from Helicobacter pylori. Bioorg Chem 2010;38:62-73. [PMID: 20036411 DOI: 10.1016/j.bioorg.2009.11.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
80 Tremaine WJ. Equipoise, H. pylori, and Musketeers – Choosing an Appropriate Standard Clinical Care Regimen. Helicobacter 2008;13:79-80. [DOI: 10.1111/j.1523-5378.2008.00594.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
81 Kim JS, Ji JS, Choi H, Kim JH. Sequential therapy or triple therapy for Helicobacter pylori infection in Asians: systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2014;38:118-125. [PMID: 24238722 DOI: 10.1016/j.clinre.2013.10.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
82 Di Caro S, Franceschi F, Mariani A, Thompson F, Raimondo D, Masci E, Testoni A, La Rocca E, Gasbarrini A. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis. 2009;41:480-485. [PMID: 18974025 DOI: 10.1016/j.dld.2008.09.013] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
83 Liou J, Chen C, Fang Y, Chen P, Chang C, Chou C, Chen M, Tseng C, Lee J, Yang T, Chiu M, Yu J, Kuo C, Luo J, Hsu W, Hu W, Tsai M, Lin J, Shun C, Twu G, Lee Y, Bair M, Wu M, Liou J, Lee Y, Lin J, Wu C, Wu J, Chen C, Lin C, Fang Y, Bair M, Luo J, Wu M, Cheng T, Tseng P, Chiu H, Chang C, Yu C, Chiu M, Chen Y, Hu W, Chou C, Tai C, Lee C, Wang W, Chang W; Members of the Taiwan Gastrointestinal Disease and Helicobacter Consortium. 14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial. Journal of Antimicrobial Chemotherapy 2018;73:2510-8. [DOI: 10.1093/jac/dky183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
84 Quek C, Pham ST, Tran KT, Pham BT, Huynh LV, Luu NB, Le TK, Quek K, Pham VH. Antimicrobial susceptibility and clarithromycin resistance patterns of Helicobacter pylori clinical isolates in Vietnam. F1000Res 2016;5:671. [PMID: 27583131 DOI: 10.12688/f1000research.8239.1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
85 Lok CH, Zhu D, Wang J, Ren YT, Jiang X, Li SJ, Zhao XY. Phenotype and Molecular Detection of Clarithromycin and Levofloxacin Resistance in Helicobacter pylori Clinical Isolates in Beijing. Infect Drug Resist 2020;13:2145-53. [PMID: 32753910 DOI: 10.2147/IDR.S249370] [Reference Citation Analysis]
86 Mohammadi A, Khanbabaei H, Zandi F, Ahmadi A, Haftcheshmeh SM, Johnston TP, Sahebkar A. Curcumin: A therapeutic strategy for targeting the Helicobacter pylori-related diseases. Microbial Pathogenesis 2022. [DOI: 10.1016/j.micpath.2022.105552] [Reference Citation Analysis]
87 Manfredi M, Bizzarri B, de’Angelis GL. Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate. Helicobacter. 2012;17:246-253. [PMID: 22759323 DOI: 10.1111/j.1523-5378.2012.00945.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
88 Yamamichi N, Shimamoto T, Sakaguchi Y, Takahashi Y, Kodashima S, Nakayama C, Minatsuki C, Ono S, Mochizuki S, Matsuda R, Asada-Hirayama I, Niimi K, Fujishiro M, Tsuji Y, Takeuchi C, Kakimoto H, Goto O, Mitsushima T, Koike K. Categorization of upper gastrointestinal symptoms is useful in predicting background factors and studying effects and usages of digestive drugs. PLoS One 2014;9:e88277. [PMID: 24505461 DOI: 10.1371/journal.pone.0088277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
89 Sjödahl K, Lagergren J. Epidemiological aspects of gastric adenocarcinoma: are predictive diagnostics and targeted preventive measures possible? EPMA J 2010;1:461-71. [PMID: 23199088 DOI: 10.1007/s13167-010-0043-0] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
90 Chen LW, Chien RN, Chang JJ, Fang KM, Chang LC. Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study. Int J Clin Pract. 2010;64:1530-1534. [PMID: 20846200 DOI: 10.1111/j.1742-1241.2010.02482.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
91 Yoon H, Kim N, Kim JY, Park SY, Park JH, Jung HC, Song IS. Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection. J Gastroenterol Hepatol. 2011;26:44-48. [PMID: 21175792 DOI: 10.1111/j.1440-1746.2010.06477.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
92 Tonkic A, Tonkic M, Brnic D, Novak A, Puljiz Z, Simunic M. Time trends of primary antibiotic resistance of Helicobacter pylori isolates in Southern Croatia. Journal of Chemotherapy 2013;24:182-4. [DOI: 10.1179/1973947812y.0000000001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
93 Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol. 2009;24:1230-1235. [PMID: 19476562 DOI: 10.1111/j.1440-1746.2009.05829.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 4.3] [Reference Citation Analysis]
94 Arora S, Budhiraja RD. Chitosan-alginate microcapsules of amoxicillin for gastric stability and mucoadhesion. J Adv Pharm Technol Res 2012;3:68-74. [PMID: 22470897 DOI: 10.4103/2231-4040.93555] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
95 Nseir W, Diab H, Mahamid M, Abu-Elheja O, Samara M, Abid A, Mograbi J. Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study. Aliment Pharmacol Ther. 2012;36:231-238. [PMID: 22646167 DOI: 10.1111/j.1365-2036.2012.05161.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
96 Lahbabi M, Alaoui S, El Rhazi K, El Abkari M, Nejjari C, Amarti A, Bennani B, Mahmoud M, Ibrahimi A, Benajah DA. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: Result of the HPFEZ randomised study. Clin Res Hepatol Gastroenterol. 2013;37:416-421. [PMID: 23168228 DOI: 10.1016/j.clinre.2012.10.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
97 Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514-533. [PMID: 26694080 DOI: 10.1111/apt.13497] [Cited by in Crossref: 310] [Cited by in F6Publishing: 288] [Article Influence: 44.3] [Reference Citation Analysis]
98 Graham DY, Lu H, Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs. 2008;68:725-736. [PMID: 18416582 DOI: 10.2165/00003495-200868060-00001] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 4.1] [Reference Citation Analysis]
99 Chang C, Liu J, Lin H, Lin C, Tang C, Lu D, Sing Y, Chen L, Kao M, Kuo S, Lai C. Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells. European Journal of Medicinal Chemistry 2012;48:244-54. [DOI: 10.1016/j.ejmech.2011.12.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
100 Andrews PC, Busse M, Deacon GB, Ferrero RL, Junk PC, MacLellan JG, Vom A. Remarkable in vitro bactericidal activity of bismuth(III) sulfonates against Helicobacter pylori. Dalton Trans 2012;41:11798-806. [PMID: 22903621 DOI: 10.1039/c2dt31360j] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
101 Wu W, Yang Y, Sun G. Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication. Gastroenterol Res Pract 2012;2012:723183. [PMID: 22829809 DOI: 10.1155/2012/723183] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
102 Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013;18:206-214. [PMID: 23241101 DOI: 10.1111/hel.12031] [Cited by in Crossref: 172] [Cited by in F6Publishing: 145] [Article Influence: 17.2] [Reference Citation Analysis]
103 Kale-Pradhan PB, Mihaescu A, Wilhelm SM. Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta-analysis. Pharmacotherapy. 2015;35:719-730. [PMID: 26173786 DOI: 10.1002/phar.1614] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
104 Yang JC, Lin CJ. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opin Drug Metab Toxicol. 2010;6:29-41. [PMID: 19968574 DOI: 10.1517/17425250903386251] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
105 Nkuize M, De Wit S, Muls V, Ntounda R, Gomez-Galdon M, Buset M. Comparison of demographic characteristics and upper gastrointestinal endoscopy findings in HIV-positive, antiretroviral-treated patients with and without Helicobacter pylori coinfection. Helicobacter 2012;17:153-9. [PMID: 22404447 DOI: 10.1111/j.1523-5378.2011.00929.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
106 Onal IK, Gokcan H, Benzer E, Bilir G, Oztas E. What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study. Clin Res Hepatol Gastroenterol. 2013;37:642-646. [PMID: 23796974 DOI: 10.1016/j.clinre.2013.05.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
107 Liou JM, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, Wu JY, Luo JC, Liou TC, Chang WH, Tseng CH, Wu CY, Yang TH, Chang CC, Wang HP, Sheu BS, Lin JT, Bair MJ, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study. PLoS One. 2015;10:e0124199. [PMID: 25942450 DOI: 10.1371/journal.pone.0124199] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 8.4] [Reference Citation Analysis]
108 Nguyen TVH, Bengtsson C, Nguyen GK, Hoang TTH, Phung DC, Sörberg M, Granström M. Evaluation of Two Triple-Therapy Regimens with Metronidazole or Clarithromycin for the Eradication of H. pylori Infection in Vietnamese Children: a Randomized, Double-Blind Clinical Trial. Helicobacter 2008;13:550-6. [DOI: 10.1111/j.1523-5378.2008.00628.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
109 Chuah Y, Wu D, Chuah S, Yang J, Lee T, Yeh H, Chen C, Liu Y, Hsu P. Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey). Helicobacter 2017;22:e12380. [DOI: 10.1111/hel.12380] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
110 Lee JW, Kim N, Nam RH, Park JH, Choi YJ, Kim JM, Kim JS, Jung HC. GenoType HelicoDR test in the determination of antimicrobial resistance of Helicobacter pylori in Korea. Scand J Gastroenterol. 2014;49:1058-1067. [PMID: 24957849 DOI: 10.3109/00365521.2014.894117] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
111 Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, Ta L, Trinh DT, Fujioka T, Yamaoka Y. The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. J Clin Gastroenterol. 2013;47:233-238. [PMID: 23090037 DOI: 10.1097/mcg.0b013e3182676e2b] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
112 Ye CL, Liao GP, He S, Pan YN, Kang YB, Zhang ZY. Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Pharmacoepidemiol Drug Saf. 2014;23:443-455. [PMID: 24677603 DOI: 10.1002/pds.3581] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
113 Kalkan IH, Sapmaz F, Güliter S, Atasoy P. Severe gastritis decreases success rate of Helicobacter pylori eradication. Wien Klin Wochenschr 2016;128:329-34. [PMID: 26637331 DOI: 10.1007/s00508-015-0896-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
114 Kang JM, Kim N, Lee DH, Park YS, Kim JS, Chang IJ, Song IS, Jung HC. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage. J Gastroenterol Hepatol. 2008;23:1287-1291. [PMID: 18637061 DOI: 10.1111/j.1440-1746.2008.05392.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
115 Ryan KA, O’Hara AM, van Pijkeren JP, Douillard FP, O’Toole PW. Lactobacillus salivarius modulates cytokine induction and virulence factor gene expression in Helicobacter pylori. J Med Microbiol. 2009;58:996-1005. [PMID: 19528183 DOI: 10.1099/jmm.0.009407-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 3.9] [Reference Citation Analysis]
116 Thiraworawong T, Spinler JK, Werawatganon D, Klaikeaw N, Venable SF, Versalovic J, Tumwasorn S. Anti-inflammatory properties of gastric-derived Lactobacillus plantarum XB7 in the context of Helicobacter pylori infection. Helicobacter. 2014;19:144-155. [PMID: 24387083 DOI: 10.1111/hel.12105] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
117 Vilaichone RK, Yamaoka Y, Shiota S, Ratanachu-ek T, Tshering L, Uchida T, Fujioka T, Mahachai V. Antibiotics resistance rate of Helicobacter pylori in Bhutan. World J Gastroenterol 2013; 19(33): 5508-5512 [PMID: 24023494 DOI: 10.3748/wjg.v19.i33.5508] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
118 Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017;8:123-30. [DOI: 10.1016/j.jgar.2016.11.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
119 Diab M, El-shenawy A, El-ghannam M, Salem D, Abdelnasser M, Shaheen M, Abdel-hady M, El-sherbini E, Saber M. Detection of antimicrobial resistance genes of Helicobacter pylori strains to clarithromycin, metronidazole, amoxicillin and tetracycline among Egyptian patients. Egyptian Journal of Medical Human Genetics 2018;19:417-23. [DOI: 10.1016/j.ejmhg.2018.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
120 Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, Cavallo R, Antonelli G, Vaira D. Antibiotic Resistance and Therapy Outcome in H. pylori Eradication Failure Patients. Antibiotics (Basel) 2020;9:E121. [PMID: 32183165 DOI: 10.3390/antibiotics9030121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
121 Rajabnia M, Sadeghi A, Abdi S, Găman M, Zali M, Salehi N, Yadegar A, Rahmani K. Effect of Statins on <b><i>Helicobacter pylori</i></b> Eradication Rate: A Systematic Review and Meta-Analysis. GE Port J Gastroenterol. [DOI: 10.1159/000518597] [Reference Citation Analysis]
122 Chen M, Wu M, Chen C, Chen C, Fang Y, Bair M, Chang C, Lee J, Hsu W, Luo J, Lin J, Liou J; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials. Journal of Antimicrobial Chemotherapy 2017;72:3481-9. [DOI: 10.1093/jac/dkx320] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
123 Yang JC, Wang HL, Chern HD, Shun CT, Lin BR, Lin CJ, Wang TH. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. Pharmacotherapy. 2011;31:227-238. [PMID: 21361732 DOI: 10.1592/phco.31.3.227] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
124 Cerqueira L, Fernandes RM, Ferreira RM, Oleastro M, Carneiro F, Brandão C, Pimentel-Nunes P, Dinis-Ribeiro M, Figueiredo C, Keevil CW, Vieira MJ, Azevedo NF. Validation of a fluorescence in situ hybridization method using peptide nucleic acid probes for detection of Helicobacter pylori clarithromycin resistance in gastric biopsy specimens. J Clin Microbiol 2013;51:1887-93. [PMID: 23596234 DOI: 10.1128/JCM.00302-13] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
125 Liou J, Chen C, Chen M, Chen C, Chang C, Fang Y, Lee J, Hsu S, Luo J, Chang W, Hsu Y, Tseng C, Tseng P, Wang H, Yang U, Shun C, Lin J, Lee Y, Wu M. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. The Lancet 2013;381:205-13. [DOI: 10.1016/s0140-6736(12)61579-7] [Cited by in Crossref: 160] [Cited by in F6Publishing: 75] [Article Influence: 17.8] [Reference Citation Analysis]
126 Kwok A, Lam T, Katelaris P, Leong RW. Helicobacter pylori eradication therapy: indications, efficacy and safety. Expert Opin Drug Saf 2008;7:271-81. [PMID: 18462185 DOI: 10.1517/14740338.7.3.271] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
127 Nkuize M, Vanderpas J, Buset M, Gomez-Galdon M, Delforge M, Miendje-Deyi VY, Muls V, De Wit S. Primary antibiotic resistance of Helicobacter pylori isolates is twofold more frequent in HIV-positive than HIV-negative individuals: A descriptive observational study. Microbiologyopen 2021;10:e1184. [PMID: 34180600 DOI: 10.1002/mbo3.1184] [Reference Citation Analysis]
128 Iwamoto A, Tanahashi T, Okada R, Yoshida Y, Kikuchi K, Keida Y, Murakami Y, Yang L, Yamamoto K, Nishiumi S, Yoshida M, Azuma T. Whole-genome sequencing of clarithromycin resistant Helicobacter pylori characterizes unidentified variants of multidrug resistant efflux pump genes. Gut Pathog. 2014;6:27. [PMID: 24995043 DOI: 10.1186/1757-4749-6-27] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
129 Trespalacios AA, Otero W, Caminos JE, Mercado MM, Ávila J, Rosero LE, Arévalo A, Poutou-piñales RA, Graham DY. Phenotypic and genotypic analysis of clarithromycin-resistant Helicobacter pylori from Bogotá D.C., Colombia. J Microbiol 2013;51:448-52. [DOI: 10.1007/s12275-013-2465-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
130 Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:109-118. [PMID: 19298338 DOI: 10.1111/j.1523-5378.2009.00671.x] [Cited by in Crossref: 151] [Cited by in F6Publishing: 153] [Article Influence: 11.6] [Reference Citation Analysis]
131 Chirani AS, Ghazi M, Goudarzi M, Peerayeh SN, Soleimanjahi H, Dadashi M, Hajikhani B. A survey on chimeric UreB229-561-HpaA protein targeting Helicobacter pylori: Computational and in vitro urease activity valuation. Comput Biol Chem 2018;76:42-52. [PMID: 29929167 DOI: 10.1016/j.compbiolchem.2018.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
132 Liou JM, Chang CY, Sheng WH, Wang YC, Chen MJ, Lee YC, Hung HW, Chian H, Chang SC, Wu MS, Lin JT. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. Antimicrob Agents Chemother. 2011;55:1123-1129. [PMID: 21189342 DOI: 10.1128/aac.01131-10] [Cited by in Crossref: 44] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
133 Jung SW, Lee SW. The antibacterial effect of fatty acids on Helicobacter pylori infection. Korean J Intern Med 2016;31:30-5. [PMID: 26767854 DOI: 10.3904/kjim.2016.31.1.30] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
134 Yamamoto T, Takano T, Higuchi W, Nishiyama A, Taneike I, Yoshida K, Kanda H, Imamura Y. Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. Antimicrob Agents Chemother 2011;55:4261-6. [PMID: 21730117 DOI: 10.1128/AAC.01105-10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
135 Jiang M, Ma L, Huang Y, Wu H, Dou J, Zhou C. Antimicrobial activities of peptide Cbf-K16 against drug-resistant Helicobacter pylori infection in vitro and in vivo. Microb Pathog 2020;138:103847. [PMID: 31704464 DOI: 10.1016/j.micpath.2019.103847] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
136 Sezikli M, Cetinkaya ZA, Sezikli H, Güzelbulut F, Tiftikçi A, Ince AT, Gökden Y, Yaşar B, Atalay S, Kurdaş OO. Oxidative stress in Helicobacter pylori infection: does supplementation with vitamins C and E increase the eradication rate? Helicobacter 2009;14:280-5. [PMID: 19674132 DOI: 10.1111/j.1523-5378.2009.00686.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
137 Sezikli M, Çetinkaya ZA, Güzelbulut F, Yeşil A, Coşgun S, Kurdaş OÖ. Supplementing vitamins C and E to standard triple therapy for the eradication of Helicobacter pylori. J Clin Pharm Ther. 2012;37:282-285. [PMID: 21740452 DOI: 10.1111/j.1365-2710.2011.01286.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
138 Hagen SJ, Ohtani M, Zhou JR, Taylor NS, Rickman BH, Blackburn GL, Fox JG. Inflammation and foveolar hyperplasia are reduced by supplemental dietary glutamine during Helicobacter pylori infection in mice. J Nutr. 2009;139:912-918. [PMID: 19261732 DOI: 10.3945/jn.108.097790] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
139 Fagoonee S, Pellicano R. Helicobacter pylori: molecular basis for colonization and survival in gastric environment and resistance to antibiotics. A short review. Infect Dis (Lond) 2019;51:399-408. [PMID: 30907202 DOI: 10.1080/23744235.2019.1588472] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 12.3] [Reference Citation Analysis]
140 Chen Y, Lin K, Wang H, Yu H, Tsai K, Hsu P. The efficacies of esomeprazole- versus pantoprazole-based reverse hybrid therapy for Helicobacter pylori eradication. Adv Dig Med 2018;5:26-32. [DOI: 10.1002/aid2.13070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
141 Vakil N. Editorial: H. pylori Treatment: New Wine in Old Bottles? Am J Gastroenterol 2009;104:26-30. [DOI: 10.1038/ajg.2008.91] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
142 Bunchorntavakul C, Buranathawornsom A. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori. J Gastroenterol Hepatol 2021;36:3308-13. [PMID: 34622504 DOI: 10.1111/jgh.15700] [Reference Citation Analysis]
143 Fock KM, Graham DY, Malfertheiner P. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol. 2013;10:495-500. [PMID: 23752823 DOI: 10.1038/nrgastro.2013.96] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 8.2] [Reference Citation Analysis]
144 Hagymási K, Tulassay Z. [Peptic ulcer: facts and questions -- 2010]. Orv Hetil. 2010;151:1054-1061. [PMID: 20558352 DOI: 10.1556/oh.2010.28892] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
145 Moshafi MH, Sorkhi M, Emami S, Nakhjiri M, Yahya-Meymandi A, Negahbani AS, Siavoshi F, Omrani M, Alipour E, Vosooghi M. 5-Nitroimidazole-based 1,3,4-thiadiazoles: heterocyclic analogs of metronidazole as anti-Helicobacter pylori agents. Arch Pharm (Weinheim). 2011;344:178-183. [PMID: 21384417 DOI: 10.1002/ardp.201000013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
146 Assem M, El Azab G, Rasheed MA, Abdelfatah M, Shastery M. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. European Journal of Internal Medicine 2010;21:310-4. [DOI: 10.1016/j.ejim.2010.05.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
147 Stubljar D, Skvarc M. Helicobacter pylori vs immune system or antibiotics. World J Immunol 2015; 5(3): 142-151 [DOI: 10.5411/wji.v5.i3.142] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
148 Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr. 2010;122:413-422. [PMID: 20628905 DOI: 10.1007/s00508-010-1404-3] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
149 Owyang SY, Luther J, Kao JY. Helicobacter pylori: beneficial for most? Expert Rev Gastroenterol Hepatol 2011;5:649-51. [PMID: 22017690 DOI: 10.1586/egh.11.69] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
150 Francesco VD, Zullo A, Hassan C, Giorgio F, Rosania R, Ierardi E. Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal. World J Gastrointest Pathophysiol 2011; 2(3): 35-41 [PMID: 21860834 DOI: 10.4291/wjgp.v2.i3.35] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 71] [Article Influence: 6.6] [Reference Citation Analysis]
151 Kocsmár É, Szirtes I, Kramer Z, Szijártó A, Bene L, Buzás GM, Kenessey I, Bronsert P, Csanadi A, Lutz L, Werner M, Wellner UF, Kiss A, Schaff Z, Lotz G. Sensitivity of Helicobacter pylori detection by Giemsa staining is poor in comparison with immunohistochemistry and fluorescent in situ hybridization and strongly depends on inflammatory activity. Helicobacter 2017;22:e12387. [DOI: 10.1111/hel.12387] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
152 Holmes KP, Fang JC, Jackson BR. Cost-effectiveness of six strategies for Helicobacter pylori diagnosis and management in uninvestigated dyspepsia assuming a high resource intensity practice pattern. BMC Health Serv Res 2010;10:344. [PMID: 21176158 DOI: 10.1186/1472-6963-10-344] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
153 Fiorini G, Vakil N, Zullo A, Saracino IM, Castelli V, Ricci C, Zaccaro C, Gatta L, Vaira D. Culture-based Selection Therapy for Patients Who Did Not Respond to Previous Treatment for Helicobacter pylori Infection. Clinical Gastroenterology and Hepatology 2013;11:507-10. [DOI: 10.1016/j.cgh.2012.12.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
154 Kongchayanun C, Vilaichone RK, Pornthisarn B, Amornsawadwattana S, Mahachai V. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. Helicobacter. 2012;17:282-285. [PMID: 22759328 DOI: 10.1111/j.1523-5378.2012.00953.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
155 Bai CL, Osaki T, Yonezawa H, Hanawa T, Zaman C, Kurata S, Kamiya S, Tanaka H. In vitro and in vivo effects of the Mongolian drug Amu-ru 7 on Helicobacter pylori growth and viability. Microbiol Immunol. 2010;54:508-515. [PMID: 20840149 DOI: 10.1111/j.1348-0421.2010.00246.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
156 Federico A, Nardone G, Gravina AG, Iovene MR, Miranda A, Compare D, Pilloni PA, Rocco A, Ricciardiello L, Marmo R. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology. 2012;143:55-61.e1; quize e13-4. [PMID: 22484118 DOI: 10.1053/j.gastro.2012.03.043] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 5.6] [Reference Citation Analysis]